A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis

A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis

Abstract Background Toremifene (TOR) is a selective oestrogen receptor modulator (SERM) and has comparable efficacy to that of tamoxifen (TAM) in breast cancer patients. Herein, we compared the safety of TOR to that of TAM in the adjuvant treatment of premenopausal breast cancer. Methods This was a...

Full description

Bibliographic Details
Main Authors: Jin Hong, Jiahui Huang, Lili Shen, Siji Zhu, Weiqi Gao, Jiayi Wu, Ou Huang, Jianrong He, Li Zhu, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Cancer
Subjects:
Toremifene
Tamoxifen
Breast cancer
Premenopausal patients
Safety
Quality of life
Online Access:http://link.springer.com/article/10.1186/s12885-020-07156-x

Internet

http://link.springer.com/article/10.1186/s12885-020-07156-x

Similar Items